Compare DUO & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DUO | LITS |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6M | 25.7M |
| IPO Year | 2018 | 2003 |
| Metric | DUO | LITS |
|---|---|---|
| Price | $0.58 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 107.2K | ★ 891.8K |
| Earning Date | 08-28-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.42 | $0.69 |
| 52 Week High | $2.90 | $2.26 |
| Indicator | DUO | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 46.62 |
| Support Level | $0.57 | $1.12 |
| Resistance Level | $0.70 | $1.25 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 17.91 | 15.62 |
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China. All revenues of the Group are derived from the PRC.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.